Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

Inhibikase Therapeutics +7.51% Post

Inhibikase Therapeutics





-2.69% Post

Inhibikase Therapeutics (NASDAQ:IKT) Full Year 2023 Results

Key Financial Results

  • Net loss: US$19.0m (loss widened by 5.4% from FY 2022).
  • US$3.57 loss per share.
NasdaqCM:IKT Earnings and Revenue History March 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Inhibikase Therapeutics EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 30%.

Looking ahead, revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 3.1% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 5 warning signs for Inhibikase Therapeutics (of which 2 don't sit too well with us!) you should know about.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via